The 5-Second Trick For Imipenem
MI-CP151 was a period 1b randomised, double-blind, placebo managed, dose-escalation, multicentre examine To judge multiple intravenous doses of sifalimumab, in adult people with dermatomyositis or polymyositis (NCT00533091). Key demo objectives have been To judge the safety and tolerability of sifalimumab in dermatomyositis or polymyositis sufferer